Xylazine exacerbates fentanyl-induced respiratory depression and prevents rescue by naloxone in mice

Xylazine is a veterinary sedative and widespread adulterant of illicit opioids, where it is commonly combined with the highly potent synthetic µ opioid receptor (MOR) agonist fentanyl. Xylazine adulteration of fentanyl is associated with increased risk of lethal overdose and decreased efficacy of reversal by the MOR antagonist naloxone. Here we use whole body plethysmography in mice to show that xylazine produces profound respiratory depression at subanesthetic doses. Xylazine rapidly and dose-dependently suppressed minute ventilation, tidal volume, and respiratory frequency. These effects were dependent on α-2 adrenergic receptors and were fully blocked by coadministration of the α-2 adrenergic antagonist atipamezole. Atipamezole, administered alone, produced only modest reversal of fentanyl-induced respiratory depression. Xylazine, when combined with a dose of fentanyl with modest respiratory effects, suppressed breathing with greater efficacy than when administered alone. Strikingly, doses of naloxone sufficient to completely reverse fentanyl-induced respiratory depression were ineffective in reversing the respiratory suppression induced by xylazine-adulterated fentanyl. By contrast, combinations of naloxone with atipamezole rapidly and fully reversed the suppression of breathing induced by xylazine-adulterated fentanyl. Our results show that xylazine suppresses breathing via activation of α-2 receptors, an effect enhanced by coadministration with the MOR agonist fentanyl. Respiratory suppression inflicted by the mixture of xylazine and fentanyl resisted reversal by naloxone but was fully reversible by subsequent coadministration of both naloxone and atipamezole. These observations have profound implications for the current opioid epidemic.